PCSK9 Inhibitor Rejection Data

March 14, 2019

The Institute for Patient Access’ 2019 access report card assesses national claims data for PCSK9 inhibitors for January-December 2018.

Filter data by state, gender, ethnicity (etc.) using the maps below.

Tips: For state level data, click state of interest. To exit state level data, click state again. To create full screen map, click the arrow button in the lower right hand corner. To share, click on share icon in the lower right hand corner.

GENDER | RACE | HEART ATTACK/STROKE | CARDIOVASCULAR DISEASE | FH DIAGNOSIS | PRIOR STATIN USE

DATA BY GENDER

PCSK9 inhibitor class data for commercial claims in the 2018 calendar year. Option to filter by gender and whether a patient has suffered a heart attack or stroke in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018.

DATA BY RACE

PCSK9 inhibitor class data for commercial claims in the 2018 calendar year. Option to filter by race and whether a patient has suffered a heart attack or stroke in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018.

DATA BY HEART ATTACK/STROKE

PCSK9 inhibitor class data for commercial claims in the 2018 calendar year filtered for patients who have suffered a heart attack or stroke in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018.

DATA BY CARDIOVASCULAR DISEASE DIAGNOSIS

PCSK9 inhibitor class data for commercial claims in the 2018 calendar year filtered for patients who have been diagnosed with cardiovascular disease in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018. Option to filter by whether patient has suffered a heart attack or stroke in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018.

DATA BY FAMILIAL HYPERCHOLESTEROLEMIA (FH) DIAGNOSIS

PCSK9 inhibitor class data for commercial claims in the 2018 calendar year filtered for patients who have been diagnosed with familial hypercholesterolemia (genetically high cholesterol) in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018.  Option to filter by whether patient has suffered a heart attack or stroke in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018.

DATA BY PRIOR STATIN/EZETIMIBE USE

PCSK9 inhibitor class data for commercial claims in the 2018 calendar year filtered for patients who have been prescribed a statin or ezetimibe in the 12 months prior to being prescribed a PCSK9 inhibitor. Option to filter by whether patient has suffered a heart attack or stroke in the 12 months prior to being prescribed a PCSK9 inhibitor through December 2018.

Categorized in: